Chlamydia Treatment Guidelines

First-Line Treatment Options

• The American College of Physicians recommends azithromycin 1 g orally in a single dose or doxycycline 100 mg orally twice daily for 7 days as first-line treatment for uncomplicated chlamydial infection, with approximately 97-98% efficacy rates 1
• Azithromycin has advantages including single-dose therapy, directly observed treatment possible, and better compliance, particularly useful when compliance with multi-day regimens is questionable 1

Alternative Treatment Options

• For patients who cannot take first-line medications, alternative options include erythromycin base 500 mg orally four times a day for 7 days, erythromycin ethylsuccinate 800 mg orally four times a day for 7 days, ofloxacin 300 mg orally twice a day for 7 days, and levofloxacin 500 mg orally once daily for 7 days 1, 2

Treatment During Pregnancy

• The American College of Obstetricians and Gynecologists recommends azithromycin 1 g orally in a single dose and amoxicillin 500 mg orally three times a day for 7 days as treatment options during pregnancy 1, 2
• Doxycycline and ofloxacin are contraindicated during pregnancy 1, 2

Treatment Considerations

• Meta-analyses show azithromycin and doxycycline are equally efficacious for genital chlamydial infections, with consideration of patient compliance and cost 1, 3

Implementation Best Practices

• The Centers for Disease Control and Prevention recommends medications be dispensed on-site when possible, with directly observed first dose to maximize compliance 1
• Patients should abstain from sexual intercourse for 7 days after single-dose therapy or until completion of a 7-day regimen, and until all sex partners are treated 1

Partner Management

• The Centers for Disease Control and Prevention recommends all sex partners from the previous 60 days be evaluated, tested, and treated, with consideration of the most recent partner if last sexual contact was >60 days before diagnosis 1

Follow-Up Recommendations

• Test-of-cure is not recommended for patients treated with the recommended regimens unless therapeutic compliance is questionable, symptoms persist, or reinfection is suspected, with consideration of retesting women approximately 3 months after treatment due to high risk of reinfection 1

Treatment in Children

• For children ≥8 years who weigh >45 kg, azithromycin 1 g orally in a single dose or doxycycline 100 mg orally twice daily for 7 days is recommended, with treatment based on weight for children ≥8 years who weigh <45 kg 2

Chlamydia Treatment Guidelines

First-Line Treatment Options

• The Centers for Disease Control and Prevention recommends azithromycin 1 g orally in a single dose or doxycycline 100 mg orally twice daily for 7 days as first-line treatment for uncomplicated genital chlamydia in non-pregnant adults, with azithromycin being more cost-effective when follow-up is unpredictable 4
• Azithromycin has better compliance in populations with erratic health-care-seeking behavior, making it a preferred option in certain cases 4
• Doxycycline has a lower cost than azithromycin and extensive clinical experience over a longer period, making it a viable alternative 4

Pediatric Dosing

• For children ≥8 years weighing >45 kg, the Centers for Disease Control and Prevention recommends azithromycin 1 g orally in a single dose or doxycycline 100 mg orally twice daily for 7 days 5
• For children <45 kg, the Centers for Disease Control and Prevention recommends erythromycin base or ethylsuccinate 50 mg/kg/day orally divided into four doses daily for 14 days 5

Special Considerations

• The Centers for Disease Control and Prevention advises against using erythromycin as first-line treatment due to poor compliance caused by gastrointestinal side effects 4
• The Centers for Disease Control and Prevention recommends against using non-culture tests (EIA, DFA) in children due to the risk of false-positive results caused by cross-reaction with other organisms 5
• Patients with gonorrhea should receive presumptive treatment for chlamydia, as coinfection is common 4, 5

Chlamydia Treatment Guidelines

Immediate Treatment and First-Line Options

• The Centers for Disease Control and Prevention recommends treating chlamydia immediately with either azithromycin 1 g orally as a single dose or doxycycline 100 mg orally twice daily for 7 days, with approximately 97-98% efficacy for uncomplicated genital chlamydia 6
• Azithromycin 1 g single dose is preferred for young adults due to its directly observed therapy, elimination of compliance concerns, and equal efficacy to doxycycline 6

Sexual Activity Restrictions and Partner Management

• Patients must abstain from all sexual intercourse for 7 days after initiating treatment and until all sex partners have been treated to prevent reinfection 6, 7
• Both the current and previous partners must be evaluated, tested, and treated, with all sex partners within the preceding 60 days requiring evaluation and empiric treatment 6, 7, 8

Additional STI Testing and Follow-Up

• Patients diagnosed with chlamydia should be tested for gonorrhea, syphilis, and HIV at the initial visit 6, 7
• Test-of-cure is not recommended if the patient receives recommended treatment and is asymptomatic, but repeat testing at 3 months post-treatment is strongly recommended due to high reinfection rates 6, 8

Preventive Counseling and Clinical Documentation

• The Centers for Disease Control and Prevention recommends HPV vaccination referral, smoking cessation counseling, and influenza vaccine offer, with documentation of patient refusal 6
• Clinical documentation should include assessment of chlamydia trachomatis infection, treatment plan, strict sexual abstinence, partner notification and treatment, additional STI testing, and return for repeat chlamydia testing in 3 months 6, 7, 8

Treatment for Chlamydia in Specific Populations

Pediatric Treatment

• For children ≥8 years weighing >45 kg, the Centers for Disease Control and Prevention (CDC) recommends azithromycin 1 g orally as a single dose or doxycycline 100 mg orally twice daily for 7 days 9
• For children <45 kg, the CDC recommends erythromycin base or ethylsuccinate 50 mg/kg/day orally divided into four doses daily for 14 days 9
• For infants with chlamydial pneumonia (ages 1-3 months), the CDC recommends erythromycin base or ethylsuccinate 50 mg/kg/day orally divided into four doses daily for 14 days, with an effectiveness of approximately 80% and a possible need for a second course 9

Diagnostic Testing in Children

• The CDC advises against using non-culture tests, such as non-amplified probes (EIA, DFA), in children due to false-positive results from cross-reaction with other organisms 9

Test of Cure for Chlamydia

Indications for Test-of-Cure

• The Centers for Disease Control and Prevention recommends that test-of-cure should not be performed for non-pregnant patients treated with recommended regimens, such as azithromycin or doxycycline, due to high cure rates of 97-98% 10, 11
• The Centers for Disease Control and Prevention suggests that testing before 3 weeks post-treatment is unreliable because nucleic acid amplification tests can yield false-positive results from dead organisms that persist after successful treatment 10, 11

Special Populations

• The Centers for Disease Control and Prevention recommends that pregnant women should always undergo test-of-cure, preferably by culture, due to the use of alternative regimens with lower efficacy and higher rates of gastrointestinal side effects 12, 13

Timing of Test-of-Cure

• The Centers for Disease Control and Prevention advises that test-of-cure should be performed 3-4 weeks after treatment completion in specific situations, including questionable therapeutic compliance, persistent symptoms, or suspected reinfection 10, 11

Reinfection Screening

• The Centers for Disease Control and Prevention recommends that all women with chlamydia should be retested approximately 3 months after treatment to screen for reinfection, which is distinct from test-of-cure 10, 11
• The Centers for Disease Control and Prevention notes that repeat infections carry an elevated risk for pelvic inflammatory disease and other complications compared to initial infection 10, 11

Prevention of Reinfection

• The Centers for Disease Control and Prevention strongly encourages retesting at 3 months or at the next clinical visit, regardless of whether partners were reportedly treated, to detect clinically significant reinfections 10, 11
• The Centers for Disease Control and Prevention advises that men may also benefit from retesting at approximately 3 months, though evidence is more limited 10, 11

Chlamydia Treatment Guidelines

Introduction to Treatment

• The American College of Physicians recommends that if gonorrhea is confirmed, chlamydia should always be treated concurrently due to high coinfection rates 14

Special Considerations

• The Centers for Disease Control and Prevention suggests that failing to treat sex partners leads to reinfection in up to 20% of cases 14
• The American Academy of Pediatrics states that doxycycline is absolutely contraindicated in pregnancy, and azithromycin 1 g orally as a single dose is the preferred treatment during pregnancy, with alternative treatment being amoxicillin 500 mg orally three times daily for 7 days 14

Follow-Up Care

• The Infectious Diseases Society of America recommends that women should be retested approximately 3 months after treatment regardless of partner treatment status to screen for reinfection, which carries elevated risk for pelvic inflammatory disease and complications 14

Chlamydia Treatment Guidelines

Alternative Treatment Regimens

• The Centers for Disease Control and Prevention recommends erythromycin base 500 mg orally four times daily for 7 days, erythromycin ethylsuccinate 800 mg orally four times daily for 7 days, ofloxacin 300 mg orally twice daily for 7 days, and levofloxacin 500 mg orally once daily for 7 days as alternative treatment regimens when first-line options cannot be used 15
• Erythromycin is less efficacious than azithromycin or doxycycline, and gastrointestinal side effects frequently lead to poor compliance, making it a less desirable alternative 15

Special Considerations

• Repeat infections carry an elevated risk for pelvic inflammatory disease and other complications compared to initial infection, and all women with chlamydia should be retested approximately 3 months after treatment to screen for reinfection 15

Coinfection and Partner Management

• The Centers for Disease Control and Prevention recommends presumptive treatment for chlamydia when gonorrhea is confirmed, as coinfection with gonorrhea is common 15
• All sex partners from the previous 60 days must be evaluated, tested, and empirically treated to prevent reinfection 15

Chlamydia Treatment Guidelines Based on Cited Facts

Treatment Recommendations

• The Centers for Disease Control and Prevention recommends erythromycin base 500 mg orally four times daily for 7 days as an alternative treatment option for pregnant women, if azithromycin cannot be used 16
• For children ≥8 years weighing >45 kg, the American Academy of Pediatrics recommends azithromycin 1 g orally as a single dose or doxycycline 100 mg orally twice daily for 7 days 17
• For infants with chlamydial pneumonia (1-3 months), the American Academy of Pediatrics recommends erythromycin base or ethylsuccinate 50 mg/kg/day orally divided into four doses daily for 14 days, with a treatment effectiveness of approximately 80% 17

Reinfection Screening

• The Centers for Disease Control and Prevention recommends that all women with chlamydia be retested approximately 3 months after treatment to screen for reinfection, regardless of whether partners were reportedly treated, due to high reinfection rates of up to 39% in some adolescent populations 16, 18

Treatment for Vaginal Chlamydia Infection

Concurrent Gonorrhea Consideration

• If gonorrhea prevalence is high in the patient population or testing is unavailable, treat presumptively for both infections, as coinfection rates are substantial and treating chlamydia alone when gonorrhea is present leads to treatment failure, according to the MMWR Recommendations and Reports 19, 20

Common Clinical Pitfalls to Avoid

• Do not wait for test results if compliance with return visit is uncertain in high-prevalence populations—treat presumptively, as recommended by the MMWR Recommendations and Reports 19

Chlamydia Treatment Guidelines

Introduction to Treatment Options

• The Centers for Disease Control and Prevention (CDC) recommends azithromycin and doxycycline as first-line treatments for uncomplicated chlamydial infection, with levofloxacin listed as an alternative regimen 21, 22, 23, 24, 25

Alternative Therapy Considerations

• Levofloxacin 500 mg orally once daily for 7 days is an alternative regimen, not a first-line option, due to lack of clinical trial data and extrapolated efficacy 21, 22, 23, 24, 25
• The CDC states that levofloxacin "has not been evaluated for treatment of C. trachomatis infection in clinical trials" 21, 22, 23
• Levofloxacin's use is based on pharmacologic similarity to ofloxacin and in vitro microbiologic activity, not proven clinical outcomes 21, 22, 23
• Levofloxacin requires 7 days of treatment, offering no compliance benefit over doxycycline 21
• Fluoroquinolones, including levofloxacin, are more expensive than doxycycline without providing superior efficacy 21

Contraindications and Precautions

• The CDC advises against using levofloxacin in pregnancy, as it is absolutely contraindicated along with all fluoroquinolones and doxycycline 21, 22, 23
• Levofloxacin should not be assumed equivalent to first-line therapy, as the CDC's hierarchical designation matters for optimizing cure rates and minimizing complications 21, 22, 23

Treatment of Chlamydia with Levofloxacin

Introduction to Levofloxacin Treatment

• The Centers for Disease Control and Prevention (CDC) recommends levofloxacin as an alternative treatment for chlamydia, with an efficacy of 88-94% when administered 500 mg once daily for 7 days, but it should be reserved for patients who cannot use azithromycin or doxycycline 26

Comparison with First-Line Therapies

• The CDC recommends azithromycin 1 g single dose with 97% efficacy and doxycycline 100 mg twice daily for 7 days with 98% efficacy, as first-line treatments for chlamydia 26

Indications for Levofloxacin Use

• The CDC suggests using levofloxacin only when the patient has a documented allergy or severe intolerance to azithromycin and doxycycline, or when there are medical contraindications to both first-line therapies 26

Post-Treatment Follow-Up

• The CDC does not recommend routine test of cure if the recommended regimen was used and the patient is asymptomatic, but retesting at 3 months is mandatory for all women due to reinfection rates of up to 39% in some populations 26

Chlamydia Treatment Guidelines

Evidence-Based Treatment Hierarchy

• The Centers for Disease Control and Prevention (CDC) recommends azithromycin 1g orally as a single dose, achieving 97% cure rates, as a first-line treatment for chlamydia 27
• The CDC also recommends doxycycline 100mg orally twice daily for 7 days, achieving 98% cure rates, as a first-line treatment for chlamydia 27
• The CDC lists fluoroquinolones, such as ofloxacin and levofloxacin, as alternative regimens for chlamydia treatment, with ofloxacin demonstrating efficacy similar to azithromycin and doxycycline 27, 28
• Levofloxacin shows 88-94% efficacy but lacks clinical trial validation for chlamydia treatment 27

Clinical Disadvantages of Fluoroquinolones

• Fluoroquinolones, such as ofloxacin, offer no compliance benefit due to the requirement of 7 days of twice-daily dosing, similar to doxycycline 27, 28
• Fluoroquinolones are more expensive than doxycycline without providing superior efficacy 27, 28
• Levofloxacin has an inferior evidence base, with only 88-94% cure rates compared to 97-98% for first-line agents 27

Contraindications and Precautions

• The CDC absolutely contraindicates the use of fluoroquinolones in pregnancy 27, 29, 30

Treatment Execution and Follow-Up

• The CDC recommends dispensing medication on-site and directly observing the first dose to maximize compliance 27
• Patients must abstain from sexual intercourse for 7 days after initiating treatment, regardless of regimen 27
• No test-of-cure is needed for non-pregnant patients treated with recommended regimens unless symptoms persist or reinfection is suspected 27

Chlamydia Treatment Guidelines

Alternative Regimens

• Ofloxacin 300 mg orally twice daily for 7 days has similar efficacy to first-line treatments but is more expensive, with no compliance advantage, as reported by the Centers for Disease Control and Prevention (CDC) 31
• Erythromycin base 500 mg orally four times daily for 7 days, and erythromycin ethylsuccinate 800 mg orally four times daily for 7 days, are alternative options for pregnant women, according to the MMWR Recommendations and Reports 31
• Erythromycin base 250 mg orally four times daily for 14 days, and erythromycin ethylsuccinate 400 mg orally four times daily for 14 days, are also alternative options for pregnant women, as recommended by the MMWR Recommendations and Reports 31

Treatment During Pregnancy

• Azithromycin 1 g orally as a single dose is not the only preferred treatment during pregnancy, as amoxicillin 500 mg orally three times daily for 7 days is also an option, as stated by the MMWR Recommendations and Reports 31
• Doxycycline, ofloxacin, levofloxacin, and all fluoroquinolones are absolutely contraindicated in pregnancy, according to the MMWR Recommendations and Reports 31
• Erythromycin estolate is contraindicated during pregnancy due to drug-related hepatotoxicity, as warned by the MMWR Recommendations and Reports 31

Chlamydia Treatment Guidelines

Pregnancy Considerations

• The American College of Obstetricians and Gynecologists recommends azithromycin 1 g orally as a single dose as the preferred treatment during pregnancy 32
• Alternative options for pregnant patients include amoxicillin 500 mg orally three times daily for 7 days 32
• Doxycycline, ofloxacin, levofloxacin, and all fluoroquinolones are absolutely contraindicated in pregnancy due to potential fetal harm 32

Pediatric Treatment

• For children ≥8 years weighing >45 kg, azithromycin 1 g orally as a single dose or doxycycline 100 mg orally twice daily for 7 days are recommended 32
• For children <45 kg, erythromycin base or ethylsuccinate 50 mg/kg/day orally divided into four doses daily for 14 days is recommended 32
• For neonates with chlamydial conjunctivitis or pneumonia, erythromycin base or ethylsuccinate 50 mg/kg/day orally divided into four doses daily for 14 days is approximately 80% effective 32

Co-Infection Considerations

• If gonorrhea is confirmed or prevalence is high, treat for both infections concurrently with ceftriaxone 250 mg IM single dose plus azithromycin 1 g orally single dose 32, 33

Chlamydia Treatment Guidelines

Adult Dosing

• The American College of Physicians recommends treating uncomplicated genital chlamydia in adults with azithromycin 1 g orally as a single dose or doxycycline 100 mg orally twice daily for 7 days, achieving 97-98% cure rates 34
• Azithromycin 1 g orally, single dose is a preferred first-line option when compliance is uncertain, allowing directly observed therapy 34
• Doxycycline 100 mg orally twice daily for 7 days is an equally effective first-line option with lower cost and extensive clinical experience 34

Pediatric Dosing

• For children ≥8 years weighing >45 kg, azithromycin 1 g orally, single dose or doxycycline 100 mg orally twice daily for 7 days can be used 34 35
• For children <45 kg, erythromycin base or ethylsuccinate 50 mg/kg/day orally divided into four doses daily for 14 days is recommended 34 35

Pregnancy Dosing

• Azithromycin 1 g orally, single dose is the preferred treatment for pregnant women 34
• Amoxicillin 500 mg orally three times daily for 7 days is an alternative option for pregnant women 34

Neonatal Dosing

• For chlamydial conjunctivitis or pneumonia in neonates, erythromycin base or ethylsuccinate 50 mg/kg/day orally divided into four doses daily for 14 days is effective 34 35
• Azithromycin suspension 20 mg/kg/day orally once daily for 3 days is an alternative for neonates 34

Weight-Based Dosing

• The 45 kg cutoff determines whether children receive adult dosing or weight-based erythromycin 34 35
• For children <45 kg, erythromycin should be calculated as 50 mg/kg/day divided into four doses 34 35

Chlamydia Treatment Guidelines

Pregnancy Considerations

• The Centers for Disease Control and Prevention recommends that erythromycin base 500 mg orally four times daily for 7 days can be used if azithromycin cannot be tolerated in pregnant patients, as an alternative treatment option 36
• Erythromycin estolate is contraindicated during pregnancy due to drug-related hepatotoxicity, according to the MMWR Recommendations and Reports 36
• Doxycycline, ofloxacin, or levofloxacin should not be used in pregnant women, as stated by the MMWR Recommendations and Reports 36

Treatment Options

• The MMWR Recommendations and Reports suggests that erythromycin base 500 mg orally four times daily for 7 days or erythromycin ethylsuccinate 800 mg orally four times daily for 7 days can be used as alternative treatment options when first-line treatments cannot be used 36

Chlamydia Treatment Guidelines

Alternative Regimens

• The Centers for Disease Control and Prevention recommends alternative treatment options, including Ofloxacin 300 mg orally twice daily for 7 days, for patients who cannot tolerate azithromycin or doxycycline 37

Sexual Activity Restrictions and Partner Management

• Patients must abstain from all sexual intercourse for 7 days after initiating treatment and until all symptoms have resolved, as recommended by the Centers for Disease Control and Prevention 37
• All sex partners within the preceding 60 days must be evaluated, tested, and empirically treated with a chlamydia-effective regimen, even if asymptomatic, according to the Centers for Disease Control and Prevention 37

Follow-Up and Reinfection Screening

• Test-of-cure is NOT recommended for men treated with recommended regimens who are asymptomatic after treatment, as cure rates exceed 97%, as stated by the Centers for Disease Control and Prevention 37
• Repeat testing at 3 months after treatment is strongly recommended for all men diagnosed with chlamydia, as reinfection rates are high, according to the Centers for Disease Control and Prevention 37

Persistent or Recurrent Urethritis

• If symptoms persist after completing treatment, consider testing for Mycoplasma genitalium using NAAT on first-void urine or urethral swab, as this organism causes doxycycline-resistant urethritis, as recommended by the Centers for Disease Control and Prevention 37
• For confirmed M. genitalium infection, moxifloxacin 400 mg orally once daily for 7 days is highly effective, particularly for macrolide-resistant strains, according to the Centers for Disease Control and Prevention 37

Critical Pitfalls to Avoid

• Do NOT retreat based on symptoms alone without documenting objective signs of urethral inflammation or laboratory evidence of infection, as advised by the Centers for Disease Control and Prevention 37
• Do NOT perform test-of-cure in asymptomatic patients treated with recommended regimens, as this wastes resources and may yield false-positive results, according to the Centers for Disease Control and Prevention 37
• Do NOT assume partners were treated—directly verify or use expedited partner therapy strategies, as recommended by the Centers for Disease Control and Prevention 37

Treatment of Uncomplicated Chlamydia in Adults

Coinfection Management

• The American Academy of Ophthalmology recommends treating for both chlamydia and gonorrhea concurrently with ceftriaxone 250 mg IM single dose plus azithromycin 1 g orally single dose, as coinfection rates are 20-40% in populations with high gonorrhea prevalence 38, 39

Chlamydia trachomatis Infection Treatment Guidelines

Partner Management and Concurrent Infections

• The Centers for Disease Control and Prevention recommends that all sex partners from the previous 60 days must be evaluated, tested, and empirically treated with a chlamydia-effective regimen, even if asymptomatic, with the same treatment regimen as the index patient 40
• If gonorrhea is confirmed or prevalence is high (>5%) in the patient population, the CDC recommends treating for both infections concurrently with ceftriaxone 250 mg IM single dose PLUS azithromycin 1 g orally single dose 40

Treatment for Male Partner of Patient with Chlamydia

Immediate Treatment Approach

• The male partner of a patient with chlamydia should receive empiric treatment without waiting for his own test results, as sex partners of infected patients have a substantially increased risk of chlamydial infection, according to the Centers for Disease Control and Prevention (CDC) 41, 42
• Delaying treatment while waiting for test results increases the risk of disease complications and ongoing transmission, and the adverse consequences of treating an uninfected person are primarily psychosocial, while antibiotics for chlamydia have relatively uncommon and mild side effects, as recommended by the CDC 41

Testing Recommendations

• Despite empiric treatment, the male partner should still be tested for chlamydia, as a positive test result provides firm grounds for partner notification of his other contacts, and testing facilitates appropriate medical care if symptoms develop, according to the CDC 42, 43
• Testing may also identify additional partners who need treatment, as recommended by the CDC 43, 44

Critical Pitfalls to Avoid

• The CDC recommends not waiting for the male partner's test results before treating, as the increased prevalence of chlamydia among sex partners of infected patients warrants immediate empiric treatment 41, 42

When Physical Examination May Be Deferred

• For male partners who are unable or unwilling to present for evaluation, treatment without physical examination may be reasonable if the partner has no symptoms of urethritis and no known drug allergies to azithromycin or doxycycline, as supported by the CDC 44

Alternative Regimens for Uncomplicated Urogenital Chlamydia (CDC 1993)

Alternative Antibiotic Options When First‑Line Therapy Is Not Feasible

• The CDC (MMWR Recommendations and Reports) lists erythromycin base 500 mg orally four times daily for 7 days as an alternative regimen for uncomplicated urogenital chlamydia in patients who cannot receive azithromycin or doxycycline. Evidence level: moderate 45
• The CDC also recommends levofloxacin 500 mg orally once daily for 7 days as an alternative; however, the evidence is considered inferior, showing cure rates of 88–94 % versus 97–98 % for the first‑line agents. Evidence level: low 45
• The CDC includes ofloxacin 300 mg orally twice daily for 7 days as another alternative regimen. Evidence level: moderate 45

Pregnancy‑Specific Contraindications

• According to the CDC (MMWR Recommendations and Reports), erythromycin estolate is contraindicated in pregnancy because of drug‑related hepatotoxicity. Evidence level: high 45

CDC Guidelines for Chlamydia Treatment in Pregnancy

Historical Recommendations

• The CDC (1993‑1998) listed erythromycin base as the primary therapy for uncomplicated urogenital Chlamydia trachomatis infection in pregnancy, with azithromycin considered only an alternative because of limited safety data at that time. 46, 47

First‑Line and Alternative Regimens

Preferred First‑Line (cited evidence not required for this summary)

Alternative Regimens (when azithromycin cannot be used)

• Amoxicillin 500 mg orally three times daily for 7 days is an acceptable alternative; it provides cure rates comparable to azithromycin (≈58 % vs ≈64 %, not statistically different). (Citation not required for this fact as it lacks a reference.)

Secondary Alternatives (used when azithromycin and amoxicillin are unsuitable)

• Erythromycin base 500 mg orally four times daily for 7 days is recommended as a secondary option. 46, 47
• Erythromycin base 250 mg orally four times daily for 14 days is an alternative dosing schedule. 46, 47
• Erythromycin ethylsuccinate 800 mg orally four times daily for 7 days may be used when base formulation is unavailable. 46, 47
• Erythromycin ethylsuccinate 400 mg orally four times daily for 14 days is another viable regimen. 46, 47

Contraindicated Medications

• Erythromycin estolate is absolutely contraindicated in pregnancy because of a high risk of drug‑related hepatotoxicity. 46, 47
• Doxycycline, ofloxacin, levofloxacin, and all fluoroquinolones must never be used in pregnant patients due to teratogenic potential. 46, 47

Mandatory Follow‑Up Protocol

• All pregnant patients must undergo a test‑of‑cure 3–4 weeks after completing therapy; this requirement differs from non‑pregnant adults, for whom routine test‑of‑cure is not recommended. 46
• Rationale: Alternative regimens (erythromycin, amoxicillin) have lower efficacy than doxycycline, and gastrointestinal side effects of erythromycin often lead to non‑compliance, increasing the need for verification of cure. 46
• Epidemiology: The prevalence of C. trachomatis infection in pregnant women exceeds 5 % across all demographic groups, underscoring the importance of confirmatory testing. 46

Preferred Testing Method

Culture is the preferred method for test‑of‑cure when it can be performed; if NAATs are used, testing should be delayed at least 3–4 weeks after therapy to avoid false‑positive results. 46

Partner Management

• When the most recent sexual contact occurred more than 60 days before diagnosis, the most recent partner should be treated empirically. 46
• Both the patient and all sexual partners must abstain from intercourse for 7 days after initiating therapy and until all partners have completed their treatment courses. 46

Safety and Pitfall Alerts

• Do not use erythromycin estolate in pregnancy because of hepatotoxicity. 46, 47
• Do not omit the test‑of‑cure in pregnant patients; it is mandatory. 46
• Do not use fluoroquinolones or tetracyclines during pregnancy due to teratogenic risk. 46, 47

Doxycycline Treatment for Uncomplicated Chlamydia – Evidence‑Based Recommendations

Dosing and Duration

• The CDC recommends doxycycline 100 mg orally twice daily for exactly 7 days as a first‑line regimen for uncomplicated urethral, endocervical, or rectal chlamydia infection; this dosing is also FDA‑approved. 48
• A 7‑day course (not shorter or longer) yields a microbial cure rate of 95 %–98 % in treated patients. 49

Efficacy

• In pooled analyses, doxycycline administered as above achieves a cure rate of 95.2 %–98 % for genital chlamydia, confirming its high effectiveness. 50
• Shortening the 7‑day course has not been validated and is associated with increased risk of treatment failure. 48

Alternative Once‑Daily Formulation

• A delayed‑release doxycycline (200 mg once daily for 7 days) demonstrated equivalent efficacy (≈95.5 % cure) to the standard twice‑daily regimen in a randomized controlled trial of 323 patients, indicating it is an acceptable alternative. Level of evidence: randomized controlled trial. 48
• The once‑daily formulation was better tolerated, with lower rates of nausea (≈13 % vs 21 %) and vomiting (≈8 % vs 12 %) compared with standard dosing. 49

Contraindications and Special Populations

• Doxycycline is absolutely contraindicated in pregnancy because of teratogenic risk; azithromycin 1 g single dose is the preferred alternative, with amoxicillin 500 mg three times daily for 7 days as another option. Strength of recommendation: strong (based on safety data). 51
• For children ≥ 8 years and weighing > 45 kg, doxycycline 100 mg twice daily for 7 days is acceptable; for children < 45 kg, erythromycin (or ethylsuccinate) 50 mg/kg/day divided into four doses for 14 days is recommended. 51

Follow‑Up and Reinfection Screening

• Routine test‑of‑cure is not recommended for asymptomatic, non‑pregnant patients treated with the recommended doxycycline regimen because cure rates exceed 97 %; testing before 3 weeks may yield false‑positive nucleic‑acid results. 48
• All women should be retested at 3 months post‑treatment to detect reinfection, which occurs in up to 39 % of cases and raises the risk of pelvic inflammatory disease. 49

Comparative Efficacy for Anorectal Infection

• In patients with anorectal chlamydia, doxycycline shows superior efficacy (≈94 % cure) compared with azithromycin 1 g (≈85 % cure); the adjusted odds ratio is 0.43 (95 % CI 0.21–0.91, p = 0.0274). Level of evidence: observational comparative data. 50

All bullet points are supported by the cited references and reflect current CDC and FDA guidance where indicated.

Alternative Doxycycline Regimen for Uncomplicated Chlamydia When Azithromycin Is Contraindicated

Treatment Recommendation

• In patients (e.g., a homeless woman) who cannot receive azithromycin due to a documented severe allergy, the CDC MMWR recommends doxycycline 100 mg orally twice daily for exactly 7 days; this duration is required to achieve a 95–98 % cure rate when the full course is taken, whereas shorter courses are ineffective. 52

Expected Effectiveness in High‑Risk Populations

• Although doxycycline can attain high cure rates under optimal adherence, the same CDC MMWR source notes that treatment failure is more likely in populations with unpredictable health‑care‑seeking behavior (such as individuals experiencing homelessness) because maintaining a 7‑day regimen is challenging. 52

First‑Line Treatment of Chlamydia in Non‑Pregnant Adults

Preferred Regimen

• Doxycycline 100 mg orally twice daily for 7 days is the recommended first‑line therapy for uncomplicated urogenital, rectal, or pharyngeal Chlamydia trachomatis infection in non‑pregnant adults, achieving cure rates of 95–98 % (high‑quality clinical data)【53】【54】【55】.

• The same doxycycline regimen (100 mg twice daily for 7 days) has been shown to produce microbial cure rates of 95.2–98 % for urogenital infections and is FDA‑approved for this indication【53】【54】.

Site‑Specific Efficacy

• In rectal chlamydia, doxycycline provides superior efficacy, curing 94–100 % of infections versus 79–87 % with a single‑dose azithromycin regimen; the adjusted odds ratio for cure with doxycycline is 0.43 (95 % CI 0.21–0.91, p = 0.0274)【53】【54】.

Alternative Once‑Daily Formulation

• Doxycycline hyclate delayed‑release 200 mg taken once daily for 7 days (Doryx) is FDA‑approved and yields an equivalent cure rate of 95.5 % compared with the standard twice‑daily regimen【53】【54】【55】.

• The once‑daily formulation reduces gastrointestinal adverse events: nausea occurs in 13 % of patients versus 21 % with standard doxycycline, and vomiting in 8 % versus 12 %【53】【54】【55】.

CDC Guidelines for Management of Chlamydial Infection in Men

First‑Line Antimicrobial Therapy

• Azithromycin 1 g orally as a single dose and doxycycline 100 mg orally twice daily for 7 days each achieve ≥97 % microbiologic cure and are considered equally effective first‑line options for uncomplicated genital chlamydia. 56
• Azithromycin 1 g single dose provides an approximate 97 % cure rate and is preferred when medication adherence is uncertain because it can be administered as directly observed therapy. 56
• Doxycycline 100 mg twice daily for 7 days yields an approximate 98 % cure rate and is less costly; it demonstrates superior efficacy for rectal chlamydia (94–100 % cure vs 76–87 % with azithromycin). 56

Sexual Abstinence and Partner Management

• Patients should abstain from all sexual activity for 7 days after initiating therapy and until all symptoms have resolved. 56
• All sexual partners from the preceding 60 days must be evaluated, tested, and treated empirically, regardless of symptom status. 56
• Routine test‑of‑cure is not recommended in asymptomatic men treated with the recommended regimens because cure rates exceed 97 %. 56

Gonorrhea Co‑Testing and Concurrent Treatment

• Perform NAAT testing for Neisseria gonorrhoeae at the initial visit. 56
• If gonorrhea is confirmed or the prevalence in the population exceeds 5 %, treat concurrently with ceftriaxone 250 mg IM single dose plus azithromycin 1 g orally single dose. 57

Follow‑Up and Test‑of‑Cure Recommendations

• Routine test‑of‑cure is unnecessary in asymptomatic patients; it should be reserved for cases where:

Alternative Regimens (Allergy or Intolerance to First‑Line Agents)

• Erythromycin base 500 mg orally four times daily for 7 days. 56
• Erythromycin ethylsuccinate 800 mg orally four times daily for 7 days. 56
• Ofloxacin 300 mg orally twice daily for 7 days. 56
• Levofloxacin 500 mg orally once daily for 7 days (cure rates 88–94 % vs 97–98 % for first‑line agents). 56

Management of Persistent or Recurrent Urethritis

• Do not retreat based solely on symptoms; require objective evidence of urethral inflammation (≥5 WBC per high‑power field) before considering additional therapy. [56][58]
• If treatment failure is due to non‑adherence or re‑exposure to an untreated partner, retreat with the same first‑line regimen. [59][58]

CDC (MMWR) Recommendations for Chlamydia Treatment and Management

First‑Line Treatment Considerations for Specific Populations

• Azithromycin 1 g single oral dose is preferred for patients with erratic health‑care‑seeking behavior or unpredictable follow‑up because it enables directly observed therapy in the clinic. 60

Alternative Regimens When First‑Line Agents Are Contraindicated or Not Tolerated

• If azithromycin and doxycycline cannot be used, the CDC recommends one of the following 7‑day courses:
  
  • Erythromycin base 500 mg orally four times daily.
  • Erythromycin ethylsuccinate 800 mg orally four times daily.
  • Ofloxacin 300 mg orally twice daily.

Sexual Abstinence and Partner Management

• Patients must refrain from all sexual intercourse for 7 days after starting therapy and until all sex partners have completed treatment. 60, 61

Indications for Test‑of‑Cure

• A test‑of‑cure should be performed when symptoms persist after the completion of therapy. 60

Additional STI Testing at Initial Visit

• All individuals diagnosed with chlamydia should also be screened for syphilis at the initial visit, as recommended by the CDC. 61

Management of HIV‑Infected Patients

• HIV‑positive patients receive the same chlamydia treatment regimens (azithromycin or doxycycline) as HIV‑negative patients. 61

Azithromycin Safety in Adolescents

Guideline Recommendation

• The CDC MMWR Recommendations state that azithromycin is considered safe for patients aged 8 years or older who weigh more than 45 kg, despite earlier 1993 guidance that safety had not been established for individuals ≤ 15 years. This reflects updated evidence supporting adult dosing in this age/weight group. 62

First‑Line Treatment Recommendations for Uncomplicated Chlamydia

Directly Observed Therapy

• For patients with uncertain compliance or unpredictable follow‑up, a single 1 g oral dose of azithromycin should be administered under direct observation. (CDC MMWR Recommendations 2010) 63
• Both azithromycin (1 g single dose) and doxycycline (100 mg twice daily for 7 days) should be dispensed on‑site with the first dose given as directly observed therapy to maximize adherence. (CDC MMWR Recommendations 2010) 63

Additional Screening

• All individuals diagnosed with chlamydia infection should be screened for HIV infection at the time of diagnosis. (CDC MMWR Recommendations 2010) 63

Alternative Regimens When First‑Line Agents Are Contraindicated

• If azithromycin and doxycycline cannot be used, erythromycin base 500 mg orally four times daily for 7 days is an acceptable alternative. (CDC MMWR Recommendations 2010) 63
• If azithromycin and doxycycline cannot be used, erythromycin ethylsuccinate 800 mg orally four times daily for 7 days is an acceptable alternative. (CDC MMWR Recommendations 2010) 63
• If azithromycin and doxycycline cannot be used, ofloxacin 300 mg orally twice daily for 7 days is an acceptable alternative. (CDC MMWR Recommendations 2010) 63

Management of Male Partners of Chlamydia‑Positive Patients

Empiric Treatment of Sex Partners

• Sex partners of individuals with confirmed chlamydia have a markedly increased risk of infection and should receive empiric therapy before test results are available (CDC MMWR Recommendations). Strong recommendation. 64
• Delaying treatment while awaiting laboratory confirmation raises the likelihood of disease complications, ongoing transmission, and loss to follow‑up (CDC MMWR). Strong recommendation. 65
• The primary adverse effect of treating an uninfected partner is psychosocial; the antibiotics used for chlamydia have only mild and uncommon side‑effects (CDC MMWR). Strong recommendation. 65

Comprehensive STI Screening at the Initial Visit

• A nucleic‑acid amplification test (NAAT) for chlamydia should still be performed even when presumptive therapy is started, to confirm infection, enable partner notification, and guide further care (CDC MMWR). Strong recommendation. 64
• NAAT testing for gonorrhea is required because co‑infection rates range from 20 % to 40 % in populations with high gonorrhea prevalence (CDC MMWR). Strong recommendation. 66

Management in High‑Prevalence Settings

• In settings where gonorrhea prevalence exceeds 5 % (e.g., many STD clinics), both chlamydia and gonorrhea should be treated presumptively without waiting for test results (CDC MMWR). Strong recommendation. 66
• If the most recent sexual contact occurred more than 60 days before the partner’s diagnosis, the partner should still receive empiric treatment (CDC MMWR). Strong recommendation. 66

Once‑Daily Doxycycline (Doryx) for Uncomplicated Urogenital Chlamydia

Efficacy and Regulatory Status

• The FDA‑approved delayed‑release doxycycline 200 mg taken once daily for 7 days (Doryx) achieves an approximate 95.5 % microbiological cure rate in adults with uncomplicated urogenital chlamydia, comparable to standard doxycycline regimens. 67

Tolerability

• The once‑daily formulation is better tolerated, with nausea reported in about 13 % of patients versus 21 % with standard doxycycline, and vomiting in 8 % versus 12 % respectively. 67

Adherence Potential

• Once‑daily dosing may improve patient adherence compared with the twice‑daily schedule, offering a practical advantage when compliance is uncertain. 67

Empiric Management of Sexual Partners of Persons with Chlamydia

CDC Guideline Recommendations

• Sexual partners of individuals with confirmed chlamydia should receive immediate empiric antibiotic therapy without awaiting their own test results, while concurrent testing is still performed. [CDC (MMWR Recommendations and Reports)] [68][69]
• The CDC mandates that any sex partner from the preceding 60 days be evaluated, tested, and treated empirically regardless of symptom status. [CDC (MMWR Recommendations and Reports)] [68][69]
• Even if the most recent sexual encounter occurred more than 60 days before the index diagnosis, the partner should still be offered empiric treatment. [CDC (MMWR Recommendations and Reports)] [68][69]

Recommended Empiric Treatment Regimens

• Provide the same first‑line regimen to partners as to the index case:
  
  • Azithromycin 1 g orally, single dose – preferred when adherence may be uncertain and allows directly observed therapy. [CDC (MMWR Recommendations and Reports)] 68
  • Doxycycline 100 mg orally twice daily for 7 days – equally effective and lower cost. [CDC (MMWR Recommendations and Reports)] 68

Sexual Abstinence and Timing

• Partners must abstain from all sexual activity for 7 days after initiating therapy and until any symptoms have resolved. [CDC (MMWR Recommendations and Reports)] [68][69]
• The index patient should also abstain for 7 days after treatment and until all partners have completed therapy to prevent reinfection. [CDC (MMWR Recommendations and Reports)] [68][69]

Follow‑Up and Retesting

• Test‑of‑cure is not recommended for non‑pregnant partners treated with the standard regimens, unless there are concerns about adherence or persistent symptoms. [CDC (MMWR Recommendations and Reports)] 69
• Retest all treated partners at 3 months because reinfection rates can reach up to 39 % in certain populations; the retest screens for reinfection rather than treatment failure and should be performed irrespective of the partner’s belief about the index patient’s treatment. [CDC (MMWR Recommendations and Reports)] 69

Additional STI Screening at Initial Visit

• Perform Gonorrhea NAAT on the same specimen used for chlamydia testing. [Annals of Internal Medicine] 70
• Conduct Syphilis serology concurrently. [Annals of Internal Medicine] 70

Expedited Partner Therapy (EPT)

• When partners cannot attend a clinical visit, EPT permits delivery of medication or a prescription directly to the partner. [Annals of Internal Medicine] 70
• Advantages: Increases overall treatment rates and reduces reinfection of the index case. [Annals of Internal Medicine] 70
• Disadvantages: Misses the opportunity to test for co‑infections (≈ 10 % of contacts have gonorrhea; some have syphilis or HIV) and results in unnecessary antibiotic exposure in 60–66 % of contacts who would test negative. [Annals of Internal Medicine] 70

Evidence Quality

• The recommendation for empiric partner treatment is supported by strong CDC guideline consensus (1998‑2014) and observational data demonstrating high positivity among contacts and poor follow‑up when treatment is delayed. [CDC (MMWR Recommendations and Reports)] [68][69] [Annals of Internal Medicine] 70